THERACLION: Theraclion Results Show Strong Recovery, Allowing Ambitious Plans finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(0)
Regulatory News:
THERACLION (ISIN: FR0010120402; Memo: ALTHE, PEA-PME eligible), an innovative company specializing in ultrasound therapy (using High Intensity Focused Ultrasound or HIFU), announces that Bernard Sabrier and Unigestion, acting on their own behalf, have informed Theraclion that they have crossed the thresholds of 20% and 25% of the company s capital and voting rights. This situation results from the conversion of convertible bonds into shares and is a sign of confidence in Theraclion s capacity for innovation and development.
In addition to the provisions of the French Commercial Code and Theraclion s statutes, Bernard Sabrier s and Unigestion s increase in Theraclion s share capital comes at a time when the company is reaching a level of technological maturity with the development of SONOVEIN S for the non-invasive treatment of varicose veins, the rollout of ECHOPULSE for the treatment of thyroid nodules, and recent announcement in the treatment of breast canc
Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME eligible), an innovative company specialized in echotherapy treatment (using High Intensity Focused Ultrasound or HIFU), announces
(1)
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME eligible), an innovative company specializing in the development of medical equipment for echotherapy treatment, notably for varicose veins, today announces its sales revenues for the year 2020 and roll-out strategy for 2021.
Roll-out strategy 2021
SONOVEIN S, the last generation of SONOVEIN systems (CE marking obtained in Oct. 2020), makes SONOVEIN a strong alternative in treatment of varicose veins. It allows faster non-surgical treatment on an ambulatory basis without the need for anaestesia. Since October the company has made significant progress with their roll-out strategy. For 2021, it plans to further expand business development in new territories including Asia. Theraclion will also significantly increase SONOVEIN S installations at new key opinion leader sites. These international experts show strong interest in this distruptive technology. Once equipped, their centers of excellen
Renewed Investor Confidence in Theraclion
Additional PGE loans for 1.5M€
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company specialized in echotherapy treatment (using High Intensity Focused Ultrasound or HIFU) notably for varicose veins, announces today that it has raised €3.0 million from investors and obtaining PGE loans from Bpi France and CIC of €1.5 million.
€4.5 million in new funding allows Theraclion to stay ahead, whilst accelerating commercial rollout
In 2019 Theraclion raised first tranche of €4,8 million from investors to finance the further development of its SONOVEIN technology. This success culminated in the recent CE marking of SONOVEIN S, the second-generation breakthrough technology for non-invasive treatment of varicose veins (please see press release of October 15th this year). Initial treatments with our technological breakthroughs also confirm excellent clinical results and were received enthusia